A commensal bacterium triggers systemic antibody responses via skin lymphoid structures and can be engineered as a topical vaccine – great therapeutic potential!
Two studies in @nature.com.web.brid.gy by the Fischbach and Belkaid labs
tinyurl.com/5yahn47t
tinyurl.com/4n4btxap
